Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 13/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535964 | 1.00 | DEGS1 (0.50) | DEGS1HCAR3HCAR2 | |
| SCHEMBL29203312 | 0.83 | RAB9A (0.56) | HCAR3HCAR2 | |
| SCHEMBL4208146 | 0.81 | FDPS (0.55) | HCAR3 | |
| SCHEMBL3723734 | 0.80 | HCAR3 (0.58) | DEGS1HCAR3 | |
| SCHEMBL16554275 | 0.79 | HCAR3 (0.46) | DEGS1HCAR3HCAR2 | |
| SCHEMBL16554276 | 0.79 | HCAR3 (0.46) | DEGS1HCAR3HCAR2 | |
| SCHEMBL17925373 | 0.78 | HCAR3 (0.45) | DEGS1HCAR3HCAR2 | |
| SCHEMBL44234 | 0.74 | POLB (0.55) | — | |
| SCHEMBL503092 | 0.74 | POLB (0.55) | — | |
| SCHEMBL44233 | 0.74 | POLB (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0313094-A2 | Anticancer agent and reagent for obtaining revertants | MEIJI SEIKA KAISHA LTD. (JP) | 1989-04-26 | — | — | EP | claimed |
| US-7745454-B2 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080182850-A1 | 3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | WYETH | 2008-07-31 | — | — | US | disclosed |
| US-7365073-B2 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2005-04-21 | — | — | US | disclosed |
| US-20040266763-A1 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6803370-B2 | COMPOUNDS FOR USE IN THE TREATMENT OF ASTHMA, ALZHEIMER'S, DIABETES, ATHEROSCLEROSIS, INFLAMMATORY BOWEL DISEASE, ARTHRITIS, TUMOR METASTASIS, ISCHEMIA AND BRAIN DISORDERS | ELAN PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-6794506-B2 | TREATMENT OF INFLAMMATORY DISEASES, SUCH AS ASTHMA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, AIDS DEMENTIA, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS, TISSUE TRANSPLANTATION, TUMOR METASTASIS | ELAN PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20020052470-A1 | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-02 | — | — | US | disclosed |
| US-20020052375-A1 | 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-02 | — | — | US | disclosed |
| WO-2002008203-A2 | 3-(HETEROARYL) ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008202-A2 | ALPHA AMINO ACID DERIVATIVES--INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | DEGS1 3045/4885HCAR3 939/4885HCAR2 836/4885 |
| US-20040266763-A1 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, AADAT, ICAM1 | DEGS1 4197/4885HCAR3 226/4885HCAR2 332/4885 |
| US-20080182850-A1 | 3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, AADAT, ICAM1 | DEGS1 4197/4885HCAR3 226/4885HCAR2 332/4885 |
| US-20020052375-A1 | 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGAL | DEGS1 3911/4885HCAR3 186/4885HCAR2 300/4885 |
| US-20020052470-A1 | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | DEGS1 2910/4885HCAR3 973/4885HCAR2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.